We’re altering immune cell metabolism to resolve disease. The field of immunometabolism is a rapidly emerging and exciting area of investigation into the role of intracellular metabolic pathways in immune cells.
Total raised: $39M
Founded date: 2018
Investors 2
| Date | Name | Website |
| - | Sofinnova ... | sofinnovap... |
| - | SV Health ... | svhealthin... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.09.2023 | - | $39M | - |
Mentions in press and media 12
| Date | Title | Description |
| 02.07.2024 | Sitryx announces leadership transition | Oxford, UK – 2 July 2024 – Sitryx Therapeutics (“the Company”), a biopharmaceutical company focused on modulating immune cell metabolism to advance a new generation of therapies for chronic autoimmune and inflammatory diseases, today announ... |
| 10.04.2024 | Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis | Oxford, UK – 10 April 2024 – Sitryx Therapeutics (“the Company”), a biopharmaceutical company focused on modulating immune cell metabolism to advance a new generation of therapies for chronic autoimmune and inflammatory diseases, has nomina... |
| 08.03.2024 | On International Women's Day SV Venture Partner Ruth McKernan reflects on some achievements of SV biotech portfolio companies | On International Women’s Day it is extremely pleasing to note the vast majority of SV Health Investor’s biotech portfolio companies with women in their C-suite, many being led by female CEOs. It is one of the many reasons I was drawn to wor... |
| 04.01.2024 | Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases | Oxford, UK – 4 January 2024 – Sitryx Therapeutics (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics for chronic autoimmune and inflammatory diseases, today announces... |
| 20.12.2023 | Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission | We've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital flowing into the industry. While biotech VC investments in 2022 failed to live up to 2021's banner year, the second half still saw a steady st... |
| 27.09.2023 | Sitryx raises additional $39 million to progress development of disease-modifying therapeutics for chronic autoimmune and inflammatory diseases | Oxford, UK – 27 September 2023 – Sitryx Therapeutics (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics for chronic autoimmune and inflammatory diseases, today announ... |
| 27.09.2023 | Sitryx Therapeutics Raises $39M in Funding | Sitryx Therapeutics, an Oxford, UK-based biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics for chronic autoimmune and inflammatory diseases, raised $39m in funding. New investor Oxford... |
| 10.11.2021 | Sitryx appoints Tanya E. Borsuk, Ph.D., as Chief Business Officer | Oxford, UK – 10 November 2021 – Sitryx (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-inflammation and immuno-oncology, today announces the appointment ... |
| 15.04.2021 | Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer | Oxford, UK – 15 April 2021 – Sitryx (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation, today announces the appointment of ... |
| 18.09.2020 | SV Health Investors welcomes six new Venture Partners to the Biotech team | Boston, MA & London, UK (September 18, 2020) – SV, a leading transatlantic healthcare venture capital and growth equity firm, today announces the addition of six new Venture Partners who join the SV Biotech team. |
Show more